Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-27T11:36:21.443Z Has data issue: false hasContentIssue false
  • English
  • Français

Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period

Published online by Cambridge University Press:  19 January 2016

J Y Soh ,
M Thalayasingam ,
S Ong ,
E X L Loo ,
L P Shek  and
S S Chao
J Y Soh
Affiliation:
University Children's Medical Institute, National University Health Systems, Singapore
M Thalayasingam
Affiliation:
Department of Paediatrics, International Medical University Clinical School, Seremban, Malaysia
S Ong
Affiliation:
Department of Otolaryngology Head and Neck Surgery, National University Health Systems, Singapore
E X L Loo
Affiliation:
Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (‘A*STAR’), Singapore
L P Shek*
Affiliation:
University Children's Medical Institute, National University Health Systems, Singapore
S S Chao
Affiliation:
Department of Otolaryngology Head and Neck Surgery, National University Health Systems, Singapore
*
Address for correspondence: Dr Lynette Pei-Chi Shek, NUHS Tower Block, Level 12, 1E Kent Ridge Road, Singapore119228 E-mail: lynette_shek@nuhs.edu.sg
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Sublingual immunotherapy in patients with allergic rhinitis sensitised to house dust mites is safe, but its efficacy is controversial and sublingual immunotherapy with Blomia tropicalis has not yet been studied. This study sought to evaluate the efficacy of sublingual immunotherapy with house dust mite extract in children and adults with house dust mite allergic rhinitis over a period of two years.

Methods:

A prospective observational study was conducted of children and adults diagnosed with house dust mite allergic rhinitis who were treated with sublingual immunotherapy from 2008 to 2012. Total Nasal Symptom Scores, Mini Rhinoconjunctivitis Quality of Life scores and medication usage scores were assessed prospectively.

Results:

Thirty-nine patients, comprising 24 children and 15 adults, were studied. Total Nasal Symptom Scores and Mini Rhinoconjunctivitis Quality of Life scores dropped significantly at three months into therapy, and continued to improve. Medication usage scores improved at one year into immunotherapy.

Conclusion:

Sublingual immunotherapy with house dust mite extracts, including B tropicalis, is efficacious as a treatment for patients with house dust mite allergic rhinitis.

Keywords

Sublingual ImmunotherapyRhinitis, AllergicDust Mites, House
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 130 , Issue 3 , March 2016 , pp. 272 - 277
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Asher, MI, Montefort, S, Björkstén, B, Lai, CK, Strachan, DP, Weiland, SK et al. ; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733–43CrossRefGoogle ScholarPubMed
2Bousquet, J, Khaltaev, N, Cruz, AA, Denburg, J, Fokkens, WJ, Togias, A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN, and AllerGen). Allergy 2008;63:8–160CrossRefGoogle Scholar
3Canonica, GW, Bousquet, J, Mullol, J, Scadding, GK, Virchow, JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62:17–25CrossRefGoogle ScholarPubMed
4Wahn, U. What drives the allergic march? Allergy 2000;55:591–9CrossRefGoogle ScholarPubMed
5Gelfand, EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005;84:163–8CrossRefGoogle ScholarPubMed
6Bousquet, PJ, Bachert, C, Canonica, GW, Casale, TB, Mullol, J, Klossek, JM et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol 2010;126:666–8CrossRefGoogle ScholarPubMed
7Craig, TJ, Sherkat, A, Safaee, S. Congestion and sleep impairment in allergic rhinitis. Curr Allergy Asthma Rep 2010;10:113–21CrossRefGoogle ScholarPubMed
8Bousquet, J, Lockey, R, Malling, HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. J Allergy Clin Immunol 1998;102:558–62CrossRefGoogle ScholarPubMed
9Passalacqua, G, Guerra, L, Pasquali, M, Lombardi, C, Canonica, GW. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004;93:3–12CrossRefGoogle ScholarPubMed
10Bousquet, J. Sublingual immunotherapy: validated! Allergy 2006;61:5–6CrossRefGoogle Scholar
11Roder, E, Berger, MY, de Groot, H, van Wijk, RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008;19:197–207CrossRefGoogle ScholarPubMed
12Penagos, M, Compalati, E, Tarantini, F, Baena-Cagnani, R, Huerta, J, Passalacqua, G et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141–8CrossRefGoogle ScholarPubMed
13Wilson, DR, Lima, MT, Durham, SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4–12CrossRefGoogle ScholarPubMed
14Arlian, LG, Vyszenski-Moher, DL, Fernandez-Caldas, E. Allergenicity of the mite, Blomia tropicalis. J Allergy Clin Immunol 1993;91:1042–50CrossRefGoogle ScholarPubMed
15Caraballo, L, Puerta, L, Martínez, B, Moreno, L. Identification of allergens from the mite Blomia tropicalis. Clin Exp Allergy 1994;24:1056–60CrossRefGoogle ScholarPubMed
16Fernández-Caldas, E, Puerta, L, Caraballo, L. Mites and allergy. Chem Immunol Allergy 2014;100:234–42CrossRefGoogle ScholarPubMed
17Juniper, EF, Guyatt, GH, Andersson, B, Ferrie, PJ. Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire. Ann Allergy 1993;70:225–30Google ScholarPubMed
18Juniper, EF, Thompson, AK, Ferrie, PJ, Roberts, JN. Development and validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132–40CrossRefGoogle ScholarPubMed
19Lee, JE, Choi, YS, Kim, MS, Han, DH, Rhee, CS, Lee, CH et al. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. Ann Allergy Asthma Immunol 2011;107:79–84CrossRefGoogle ScholarPubMed
20Wise, SK, Woody, J, Koepp, S, Schlosser, RJ. Quality of life outcomes after sublingual immunotherapy. Am J Otolaryngol 2009;30:305–11CrossRefGoogle ScholarPubMed
21Kim, ST, Han, DH, Moon, IJ, Lee, CH, Min, YG, Rhee, CS. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy 2010;24:271–5CrossRefGoogle ScholarPubMed
22Yonekura, S, Okamoto, Y, Sakurai, D, Horiguchi, S, Hanazawa, T, Nakano, A et al. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. Allergol Int 2010;59:381–8CrossRefGoogle ScholarPubMed
23Ferrés, J, Justicia, JL, García, MP, Muñoz-Tudurí, M, Alvà, V. Efficacy of high-dose sublingual immunotherapy in children allergic to house dustmites in real-life clinical practice. Allergol Immunopathol (Madr) 2011;39:122–7CrossRefGoogle Scholar
24Park, IH, Hong, SM, Lee, HM. Efficacy and safety of sublingual immunotherapy in Asian children. Int J Pediatr Otorhinolaryngol 2012;76:1761–6CrossRefGoogle ScholarPubMed
25Wang, DH, Chen, L, Cheng, L, Li, KN, Yuan, H, Lu, JH et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope 2013;123:1334–40CrossRefGoogle ScholarPubMed
26Kim, SH, Mun, SJ, Han, DH, Kim, JW, Kim, DY, Rhee, CS. Three-year follow-up results of sublingual immunotherapy in patients with allergic rhinitis sensitized to house dust mites. Allergy Asthma Immunol Res 2015;7:118–23CrossRefGoogle ScholarPubMed
27de Bot, CM, Moed, H, Berger, MY, Röder, E, Hop, WC, de Groot, H et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012;23:151–9CrossRefGoogle Scholar
28Hirsch, T, Sahn, M, Leupold, W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8:21–7CrossRefGoogle ScholarPubMed
29Aydogan, M, Eifan, AO, Keles, S, Akkoc, T, Nursoy, MA, Bahceciler, NN et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomized trial. Respir Med 2013;107:1322–9CrossRefGoogle Scholar
30Tahamiler, R, Saritzali, G, Canakcioglu, S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007;117:965–9CrossRefGoogle ScholarPubMed
31Marcucci, F, Sensi, L, Di Cara, G, Salvatori, S, Bernini, M, Pecora, S et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005;16:519–26CrossRefGoogle ScholarPubMed
32Marogna, M, Spadolini, I, Massolo, A, Canonica, GW, Passalacqua, G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969–75CrossRefGoogle ScholarPubMed